LOW-DOSE CYTARABINE AFTER FAILURE OF 5-AZACITIDINE AS PALLIATIVE TREATMENT FOR ELDERLY PATIENTS WITH AML OR HIGH-RISK MDS INELIGIBLE FOR INTENSIVE CHEMOTHERAPY. A RETROSPECTIVE SINGLE CENTER ANALYSIS

被引：0
|
作者：
Jakob, C. [1 ]
Peinert, S.
Breywisch, F. [1 ]
Guenther, B. [1 ]
Dittberner, K. [1 ]
Boger, L. [1 ]
Rothmann, F. [1 ]
Maschmeyer, G. [1 ]
机构：
[1] Klinikum Ernst Bergmann, Hematol Oncol & Pallait Care, Potsdam, Germany
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E967
引用
收藏
页码：386 / 386
页数：1
相关论文
共 43 条
  • [1] Second-Line Low-Dose Cytarabine after First-Line Treatment with 5-Azacitidine in Elderly Patients with AML or High-Risk MDS Ineligible for Intensive Chemotherapy. A Retrospective Single Center Analysis
    Jakob, Christian
    Gunther, Benjamin
    Dittberner, Katharina
    Boger, Leonard
    Bleienheuft, Philipp
    Breywisch, Frank
    Rothmann, Frank
    Peinert, Stefan
    Maschmeyer, Georg
    BLOOD, 2015, 126 (23)
  • [2] A dose and schedule finding study of maintenance therapy with low-dose 5-azacitidine (AZA) after allogeneic hematopoietic stem cell transplantation (HSCT) for high-risk AML or MDS
    de Lima, Marcos
    Padua, L.
    Giralt, S.
    Hosini, C.
    Komanduri, K.
    Qazilbash, M.
    Shpall, E. J.
    Thall, P.
    Qureshi, S.
    McCormick, G.
    Tong, W.
    Popat, U.
    Soriano, A.
    Champlin, R.
    Garcia-Manero, G.
    BLOOD, 2007, 110 (11) : 884A - 885A
  • [3] Feasibility of BIBF1120 (nintedanib) combined with low-dose cytarabine in elderly patients with AML ineligible for intensive treatment.
    Krug, Utz
    Knoblauch, Nicola
    Gerss, Joachim
    Schliemann, Christoph
    Wiebe, Stefanie
    Mueller-Tidow, Carsten
    Berdel, Wolfgang E.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients
    Oran, Betul
    de Lima, Marcos
    Garcia-Manero, Guillermo
    Thall, Peter F.
    Lin, Ruitao
    Popat, Uday
    Alousi, Amin M.
    Hosing, Chitra
    Giralt, Sergio
    Rondon, Gabriela
    Woodworth, Glenda
    Champlin, Richard E.
    BLOOD ADVANCES, 2020, 4 (21) : 5580 - 5588
  • [5] Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS
    Wu, Lingyun
    Li, Xiao
    Su, Jiying
    He, Qi
    Zhang, Xi
    Chang, Chunkang
    Pu, Quan
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2011, 137 (10) : 1563 - 1569
  • [6] Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS
    Lingyun Wu
    Xiao Li
    Jiying Su
    Qi He
    Xi Zhang
    Chunkang Chang
    Quan Pu
    Journal of Cancer Research and Clinical Oncology, 2011, 137 : 1563 - 1569
  • [7] Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy
    Laloi, Louise
    Billotey, Natacha Chaumard
    Dumas, Pierre-Yves
    Paul, Franciane
    Villate, Alban
    Simand, Celestine
    Fornecker, Luc
    Puisset, Florent
    Bertoli, Sarah
    Simonet, Marion Boissard
    Laribi, Kamel
    Houyou, Dyhia
    Santagostino, Alberto
    Michel, Claire
    Guepin, Gabrielle Roth
    Guerineau, Elodie
    Tabrizi, Reza
    Hunault, Mathilde
    Giltat, Aurelien
    Kaphan, Eleonore
    Bulabois, Claude
    Cartet, Elodie
    Rocher, Clement
    Lachenal, Florence
    Morisset, Stephane
    Recher, Christian
    Pigneux, Arnaud
    Belhabri, Amine
    Michallet, Mauricette
    Michallet, Anne-Sophie
    CANCER MEDICINE, 2023, 12 (06): : 7175 - 7181
  • [8] Azacitidine and low-dose cytarabine in palliative patients with acute myeloid leukemia and high bone marrow blast counts - a retrospective single-center experience
    Radujkovic, Aleksandar
    Dietrich, Sascha
    Bochtler, Tilmann
    Kraemer, Alwin
    Schoening, Tilman
    Ho, Anthony D.
    Dreger, Peter
    Luft, Thomas
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2014, 93 (02) : 112 - 117
  • [9] SALVAGE VENETOCLAX COMBINATION THERAPY IN PATIENTS WITH AML TRANSFORMATION AFTER AZACITIDINE THERAPY FAILURE FOR HIGH-RISK MDS - SINGLE-CENTER EXPERIENCE
    Minarik, L.
    Stopka, T.
    Zemanova, Z.
    Sotakova, S.
    Jonasova, A.
    LEUKEMIA RESEARCH, 2023, 128
  • [10] Maintenance treatment with 5-azacitidine for patients with high risk myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS (MDS-AML) in complete remission (CR) after induction chemotherapy
    Groevdal, M.
    Kahn, R.
    Jansson, M.
    Aggerholm, A.
    Antunovic, P.
    Astermark, J.
    Bernell, P.
    Engstroem, L.
    Kjeldsen, L.
    Linder, O.
    Nilsson, L.
    Olsson, A.
    Skovholm, M.
    Tangen, J.
    LEUKEMIA RESEARCH, 2009, 33 : S49 - S50
12345